Highlights
IIA supported (ever)1 patent
About
Antibody for Treating Autoimmune Disorders
ProtAb Ltd is focused on the development of therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. The companys first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA). ProtAb operates as a subsidiary of Hadasit Bio-Holdings Ltd (HBL). HBL is a publicly traded subsidiary of Hadasit Ltd, the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel.
Identity
| Name | ProtAb |
|---|---|
| Slug | protab |
| Type / kind | startup |
| Crunchbase ID | ProtAb |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6oms8JDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2017 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Jerusalem, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
antibodiesinflammatory-diseasesbiotechnologydiabetespharmaceuticalstherapeuticsautoimmune-diseases
Funding
| Total raised | $8.9M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}